Notes on the Design of Bioequivalence Study:
Abacavir / Dolutegravir / Lamivudine

Notes on the design of bioequivalence studies with products invited for submission to the WHO Prequalification Team – Medicines (PQT/MED) are issued to aid manufacturers with the development of their product dossier. Deviations from the approach suggested below can be considered acceptable if justified by sound scientific evidence.


Below, additional specific guidance is provided on the invited immediate release products containing abacavir, dolutegravir and lamivudine.

**Pharmacokinetics of abacavir, dolutegravir and lamivudine**

Maximum abacavir concentrations are observed in plasma within 0.5 to 3.0 hours of dosing in the fasted state (median Tmax of 1 - 1.5 hour). The half-life of abacavir is 1.5 hours. Food delayed absorption and decreased Cmax of abacavir, but did not affect overall plasma concentrations (AUC). Therefore, abacavir can be taken with or without food.

Maximum dolutegravir concentrations are observed in plasma with a median within 2.0 to 3.0 hours of dosing in the fasted state. The half-life of dolutegravir is 14 hours approximately. Food increased the extent and slowed the rate of absorption of dolutegravir. Bioavailability of dolutegravir depends on meal content: low, moderate, and high fat meals increased dolutegravir AUC0-inf by 33%, 41%, and 66%, increased Cmax by 46%, 52%, and 67%, prolonged Tmax to 3, 4, and 5 hours from 2 hours under fasted conditions, respectively. These increases may be clinically relevant in the presence of certain integrase class resistance. Therefore, dolutegravir is recommended to be taken with food by patients infected with HIV with integrase class resistance.

Maximum lamivudine concentrations are observed in plasma within 0.5 to 3.0 hours of dosing in the fasted state (median Tmax of 1 - 1.5 hour). The half-life of lamivudine is 5-7 hours. Co-administration of lamivudine with food results in a delay of Tmax and a lower Cmax (decreased by 47%). However, the extent (based on the AUC) of lamivudine absorption is not influenced. Therefore, lamivudine can be taken with or without food.

**Guidance for the design of bioequivalence studies**

Taking into account the pharmacokinetic properties of abacavir, dolutegravir and lamivudine, the following guidance with regard to the study design should be taken into account.

**Study design:** A single-dose cross-over design is recommended.

**Dose:** As the EoI only includes the strength 60mg /5 mg / 30 mg as dispersible tablet, the bioequivalence study should be conducted with this strength.

When conducting bioequivalence studies, it is essential to administer the test and the comparator product according to the corresponding instructions for use (i.e., fully disperse the tablets for oral suspension in 20 mL of drinking water, swirl the suspension so that no lumps remain. After full dispersion, administer the oral suspension within 30 minutes of mixing). The bioequivalence study should be conducted employing the intended method of administration. It is considered incorrect to standardise the volume of liquid in any case (e.g., administering a glass
of water after the intake of a dispersible tablet or rinsing the container where a dispersible tablet has been suspended with the remaining liquid of a glass of water) because this standardisation does not occur in real life conditions.

**Fasted/fed:** The bioequivalence study should be conducted in the fasting state as abacavir / dolutegravir / lamivudine can be taken irrespective of meals.

**Subjects:** Healthy adult subjects should be recruited. It is not necessary to include patients in the bioequivalence study.

**Parent or metabolite data for assessment of bioequivalence:** The parent drugs are considered to best reflect the biopharmaceutical quality of the product. Therefore, bioequivalence should be based on the determination of the parent compounds.

**Sample size:** Abacavir, dolutegravir and lamivudine Cmax seem to be moderately variable (15 - 25% approx.). These data may facilitate the calculation of a sufficient sample size for a cross-over bioequivalence study.

**Washout:** Taking into account the largest elimination half-life of these drugs corresponds to dolutegravir and it is approximately 14 hours in healthy volunteers, a washout period of seven days is considered sufficient to prevent carry over.

**Blood sampling:** The blood sampling should be intensive for the first four hours after administration to properly characterize the Cmax of abacavir, dolutegravir and lamivudine. It is not necessary to take blood samples beyond 12 hours for the characterization of abacavir pharmacokinetics, 72 h for dolutegravir and 24 hours for lamivudine. For example, samples can be taken pre-dose and at 0.16, 0.33, 0.50, 0.67, 0.83, 1.00, 1.16, 1.33, 1.50, 1.75, 2.00, 2.16, 2.33, 2.50, 3.00, 3.50, 4.00, 5.00, 6.00, 8.00, 12.00, 16.00, 24.00, 36.00, 48.00 and 72 h hours.

**Analytical considerations:** Information currently available to PQT/MED indicates that it is possible to measure abacavir, dolutegravir and lamivudine in human plasma using LC-MS/MS analytical methodology. The bioanalytical method should be sufficiently sensitive to detect concentrations that are 5% of the Cmax in most profiles of each formulation (test or comparator).

**Statistical considerations:** The data for abacavir, dolutegravir, and lamivudine should meet the following bioequivalence standards in a single-dose cross-over design study:

- The 90% confidence interval of the relative mean AUC\(_{0-t}\) of the test to comparator product should be within 80.00 – 125.00%
- The 90% confidence interval of the relative mean C\(_{\text{max}}\) of the test to comparator product should be within 80.00 – 125.00%.